ING Groep NV Trims Position in DaVita Inc. (NYSE:DVA)

ING Groep NV reduced its position in DaVita Inc. (NYSE:DVA - Free Report) by 58.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,571 shares of the company's stock after selling 16,492 shares during the period. ING Groep NV's holdings in DaVita were worth $1,897,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of DVA. Mirae Asset Global Investments Co. Ltd. raised its position in DaVita by 1.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company's stock worth $776,000 after acquiring an additional 70 shares during the period. Wedmont Private Capital raised its holdings in DaVita by 4.4% in the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company's stock worth $280,000 after purchasing an additional 75 shares during the period. Blue Trust Inc. lifted its position in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after purchasing an additional 78 shares in the last quarter. First Trust Direct Indexing L.P. grew its holdings in DaVita by 2.9% during the third quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company's stock valued at $500,000 after purchasing an additional 86 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in DaVita by 0.3% in the third quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company's stock worth $6,036,000 after buying an additional 126 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

Insider Activity at DaVita

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the business's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Joel Ackerman sold 64,029 shares of the firm's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares of the company's stock, valued at $17,286,243.86. The trade was a 36.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 156,086 shares of company stock valued at $24,807,161 over the last 90 days. 2.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DVA has been the subject of a number of recent research reports. UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Bank of America raised their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research report on Wednesday, August 7th. Truist Financial lifted their target price on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. TD Cowen raised their price target on DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a report on Wednesday, July 24th. Finally, Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $161.80.

DaVita Price Performance

Shares of DaVita stock traded up $5.97 during trading on Friday, reaching $160.33. 1,162,981 shares of the stock traded hands, compared to its average volume of 923,358. DaVita Inc. has a 52-week low of $92.68 and a 52-week high of $168.50. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The business has a fifty day simple moving average of $157.78 and a two-hundred day simple moving average of $147.56. The company has a market capitalization of $13.15 billion, a price-to-earnings ratio of 17.30, a P/E/G ratio of 0.90 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.85 EPS. Sell-side analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.